Mission Statement, Vision, & Core Values (2026) of Chengdu Kanghong Pharmaceutical Group Co., Ltd.

Founded in 1996 and headquartered in Sichuan, Chengdu Kanghong Pharmaceutical Group Co., Ltd. (002773.SZ) has grown into a global player with a market capitalization of about $6 billion as of late 2025, a workforce exceeding 6,000 professionals including some 1,500 R&D staff, and over 20 FDA‑approved ophthalmic products-data that underscore how its mission to 'fundamentally improve patients' physical ability and social medical efficacy' and vision to 'become a first-class enterprise in the global pharmaceutical and healthcare markets' translate into measurable scale; with specialization in ophthalmic, central nervous, digestive, and endocrine therapies, 12 subsidiaries across China, the United States, Singapore, and Israel, and core values of Integrity, Innovation, Responsibility, Collaboration and Customer Focus, Kanghong's strategic investments and international footprint invite a closer look at how these elements drive its R&D, manufacturing, and global distribution endeavors

Chengdu Kanghong Pharmaceutical Group Co., Ltd (002773.SZ) - Intro

• Founded: 1996 (Chengdu, Sichuan Province, China)
• Global footprint: 12 subsidiaries across China, the United States, Singapore, and Israel
• Employees: >6,000 professionals
• R&D workforce: ~1,500 R&D personnel
• Market capitalization: ~USD 6 billion (late 2025)
• Ophthalmic product portfolio: >20 FDA‑approved ophthalmic products (including levofloxacin eye drops and sodium hyaluronate-based artificial tears)

• Advance patient-centered healthcare by discovering, developing and delivering high-quality medicines that address unmet medical needs in ophthalmology, neurology, gastroenterology and endocrinology.
• Integrate rigorous science with scalable manufacturing to ensure safety, accessibility and sustainable growth.

• Be recognized as a global innovator in specialty pharmaceuticals, with leading positions in ophthalmic therapies and a diversified presence across multiple therapeutic areas and markets.
• Leverage cross-border partnerships and a strong R&D engine to translate cutting-edge science into affordable, widely available treatments.

• Scientific excellence - sustained investment in R&D and evidence-driven development.
• Patient focus - prioritize clinical benefit, safety and accessibility.
• Integrity and compliance - adhere to global regulatory and ethical standards in operations and commercialization.
• Collaboration - foster internal multidisciplinary teamwork and external partnerships (academic, industry, global subsidiaries).
• Continuous improvement - scale manufacturing quality and operational efficiency while expanding therapeutic reach.

• Expand ophthalmic leadership via lifecycle management, additional regulatory approvals and new formulations.
• Strengthen global commercialization through 12+ subsidiaries and targeted market entries.
• Maintain R&D intensity with ~1,500 dedicated researchers and translational pipelines across core therapy areas.
• Invest in manufacturing capacity and quality systems to support global supply chains and regulatory compliance.

Chengdu Kanghong Pharmaceutical Group Co., Ltd (002773.SZ) - Overview

Mission Statement

Chengdu Kanghong Pharmaceutical Group Co., Ltd (002773.SZ) states its mission as: 'fundamentally improve patients' physical ability and social medical efficacy, and promote the progress of human health-health for the world and benefit all living beings.' This mission frames the company's strategic priorities across R&D, clinical development, manufacturing and global expansion.

• Patient-centered focus: prioritizing therapies that restore core physical function and improve long-term quality of life.
• Global health ambition: developing and commercializing products with cross-border applicability and global public-health impact.
• R&D-driven growth: consistent allocation of capital and human resources to discover and commercialize innovative medicines.
• Broad stakeholder benefit: commitment to social medical efficacy, health equity and access.

Operationalizing the mission has driven measurable investments and outcomes. Key tangible indicators (most recent fiscal year figures):

Vision and strategic implications

• Deliver transformative therapies for neurological and ophthalmic diseases where Kanghong has built clinical expertise and intellectual-property portfolios.
• Scale global commercialization: leveraging licensing, joint ventures and overseas subsidiaries to increase access and uptake internationally.
• Embed high R&D intensity: keeping R&D spend as a significant portion of revenue to sustain pipeline depth and first-in-class opportunities.
• Advance manufacturing and supply resilience to ensure dependable global distribution of key biologics and small molecules.

Core values shaping daily practice

• Science-first: evidence-based decision making and rigorous clinical development.
• Patient welfare: design and measure success by patient functional outcomes and social medical efficacy.
• Integrity and compliance: adherence to global regulatory standards and ethical commercialization.
• Collaboration: partnerships with academic institutions, CROs and global pharma to accelerate innovation.

Examples of mission-driven outcomes

• High R&D intensity has produced multiple late-stage candidates and a growing biologics portfolio targeting central nervous system and ophthalmic indications.
• Commercial rollouts in Asia and selective entry into Europe and Latin America through regional affiliates and licensing arrangements.
• Operational metrics show reinvestment into production capacity upgrades and international regulatory submissions to broaden patient access.

For a financial deep-dive and investor-oriented breakdown of Chengdu Kanghong's performance and balance-sheet dynamics, see: Breaking Down Chengdu Kanghong Pharmaceutical Group Co., Ltd Financial Health: Key Insights for Investors

Chengdu Kanghong Pharmaceutical Group Co., Ltd (002773.SZ) - Mission Statement

• Commitment to excellence across R&D, manufacturing, quality assurance, and customer service.
• Global market orientation: pursuing approvals, partnerships, and commercialization outside China.
• Investing in next‑generation biologics and ophthalmic therapies (including the flagship anti‑VEGF Conbercept).
• Driving sustainable growth while adhering to international compliance and safety standards.

• Operational priorities driven by the vision:
  • Scale up global registration and commercialization of core biologics.
  • Maintain high R&D throughput across preclinical and clinical programs.
  • Strengthen manufacturing capacity to meet international GMP standards.
• Governance & capital markets alignment:
  • Public listing (002773.SZ) supports access to capital for global expansion.
  • Market cap (~$6B) used to benchmark progress but the company reiterates long‑term scientific goals over short‑term valuation.

Chengdu Kanghong Pharmaceutical Group Co., Ltd (002773.SZ) - Vision Statement

• Integrity: operating transparently and in full compliance with legal and regulatory standards to build trust with patients, partners, investors, and regulators.
• Innovation: prioritizing breakthrough research-particularly in ophthalmology and biologics-by allocating significant resources to R&D and pipeline development.
• Responsibility: committing to sustainable development, occupational health and safety, and community engagement to reduce environmental impact and support local stakeholders.
• Collaboration: forging partnerships with universities, hospitals, CROs, and global research organizations to accelerate drug discovery, clinical development, and technology transfer.
• Customer Focus: centering product development, commercial strategies, and patient support services on improved clinical outcomes and access to therapies.

• Advance and expand the ophthalmology portfolio-leading with anti-VEGF biologics-while diversifying into other therapeutic areas with high unmet need.
• Maintain robust R&D intensity and pipeline progression through in-house programs and external collaborations.
• Scale commercial capabilities domestically and explore selective international expansion pathways, including licensing and partnerships.
• Embed ESG (environmental, social, governance) practices across operations and reporting to meet stakeholder expectations.

• R&D investment: sustained funding for early-stage discovery, clinical trials, and regulatory filings to strengthen the biologics pipeline.
• Commercial execution: focused promotion and patient-support programs to maximize adoption of core products in target markets.
• Partnership strategy: licensing, co-development, and academic collaborations to de-risk innovation and accelerate time-to-market.
• Governance and compliance: stringent quality systems and regulatory affairs capabilities to ensure ethical conduct and product safety.